Filtered By:
Specialty: Cardiology
Drug: Insulin

This page shows you your search results in order of date. This is page number 11.

Order by Relevance | Date

Total 191 results found since Jan 2013.

Lifestyle Choices Fuel Epidemics of Diabetes and Cardiovascular Disease among Asian Indians
Within the next 15 years, India is projected to overtake China as the world’s most populous nation. Due to the rapid pace of urbanization and modernization fueling population growth, in conjunction with a genetic predisposition to insulin resistance, India is suffering a rising epidemic of non-communicable diseases (NCDs), including coronary artery disease (CAD), type 2 diabetes mellitus (T2DM), and stroke. In addition to the genetic predisposition, major negative lifestyle factors are contributing to the alarming outbreak of cardiovascular disease (CVD) among the Asian Indian population; these factors include:1) a diet ...
Source: Progress in Cardiovascular Diseases - August 12, 2015 Category: Cardiology Authors: Evan L. O’Keefe, James J. DiNicolantonio, Harshal Patil, John H. Helzberg, Carl J. Lavie Source Type: research

Comparison of outcomes after everolimus-eluting stent implantation in diabetic versus non-diabetic patients in the Tokyo-MD PCI study.
CONCLUSIONS: In this all-comer, observational study, the risk of TLR was greater in IRDM compared with non-DM after EES implantation, while the increased risk for TLR from NIRDM did not reach statistical significance. PMID: 26130583 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - June 27, 2015 Category: Cardiology Authors: Konishi Y, Ashikaga T, Sasaoka T, Kurihara K, Yoshikawa S, Isobe M Tags: J Cardiol Source Type: research

High Event Rate After a First Percutaneous Coronary Intervention in Patients With Diabetes Mellitus: Results From the Swedish Coronary Angiography and Angioplasty Registry Coronary Interventions
Conclusions— The prognosis after a first percutaneous coronary intervention is more severe in patients with diabetes mellitus, in particular, in patients treated with insulin, with higher rates of mortality, cardiovascular events, and stent thrombosis over the following 5 years.
Source: Circulation: Cardiovascular Interventions - May 29, 2015 Category: Cardiology Authors: Ritsinger, V., Saleh, N., Lagerqvist, B., Norhammar, A. Tags: Type 2 diabetes, Catheter-based coronary interventions: stents Source Type: research

Insulin Resistance and Risk of Cardiovascular Disease in Postmenopausal Women: A Cohort Study From the Women's Health Initiative Original Articles
Conclusions— Measures of insulin resistance were no longer associated with CVD risk after adjustment for high-density lipoprotein-cholesterol and did not provide independent prognostic information in postmenopausal women without diabetes mellitus. Clinical Trial Registration Information— URL: http://www.clinicaltrial.gov. Unique identifier: NCT00000611.
Source: Circulation: Cardiovascular Quality and Outcomes - May 19, 2015 Category: Cardiology Authors: Schmiegelow, M. D., Hedlin, H., Stefanick, M. L., Mackey, R. H., Allison, M., Martin, L. W., Robinson, J. G., Hlatky, M. A. Tags: Health policy and outcome research, Risk Factors, Acute myocardial infarction, Acute Cerebral Infarction, Epidemiology Original Articles Source Type: research

Relationship Between Insulin-like Growth Factor Binding Protein-2 and Left Ventricular Stroke Volume in Patients with Aortic Stenosis
Conclusions In this study, we documented that lower IGFBP-2 levels are independently associated with lower SVi, a powerful predictor of worse outcomes in the mild to moderate AS population. Teaser In aortic stenosis (AS) patients, LV remodeling and function vary extensively from one patient to another. Considering the associations between circulating IGFBP-2 and markers of the metabolic syndrome, the aim of the study was to examine the relationship between circulating IGFBP-2 and left ventricle (LV) pump function as measured by stroke volume index in AS patients with preserved LV ejection fraction.
Source: Canadian Journal of Cardiology - April 30, 2015 Category: Cardiology Source Type: research

G-Protein β 3 -Subunit Gene C825T Polymorphism and Cardiovascular Risk: An Updated Review
Abstract Hypertension is a common disorder of multifactorial origin that constitutes a major risk factor for cardiovascular events such as stroke and myocardial infarction. The subunits of the heterotrimeric G proteins are attractive candidate gene products for susceptibility to hypertension, obesity and insulin resistance syndrome. A polymorphism (825C/T) in exon 10 of the GNB3 gene, encoding for the Gβ3 subunit, has been described. The 825T allele is associated with alternative splicing of the gene and formation of a truncated but functionally active β3 subunit. Many studies have investigated whether carriers ...
Source: High Blood Pressure and Cardiovascular Prevention - April 23, 2015 Category: Cardiology Source Type: research

Risk of Stroke in Chronic Heart Failure Patients without Atrial Fibrillation: Analysis of the CORONA and GISSI-HF Trials.
CONCLUSIONS: -A small number of demographic and clinical variables identified a subset of HF patients without AF at high risk of stroke. PMID: 25810334 [PubMed - as supplied by publisher]
Source: Circulation - March 25, 2015 Category: Cardiology Authors: Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, Wikstrand J, Kjekshus J, Lip GY, Maggioni AP, Tavazzi L, Lees KR, McMurray JJ, Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and GISSI-Heart F Tags: Circulation Source Type: research

Is the Long-Term Outcome of PCI or CABG in Insulin-Treated Diabetic Patients Really Worse Than Non-Insulin-Treated Ones?
In a recent issue of the Journal, Dangas et al. (1), after analyzing 1,850 subjects from the FREEDOM (Comparison of Two Treatments for Multivessel Coronary Artery Disease in Individuals With Diabetes) trial, found that in patients with diabetes and multivessel coronary artery disease, the rate of major adverse cardiovascular events (death, myocardial infarction, or stroke) is higher in patients treated with insulin than it is in those not treated with insulin. Their work is excellent, and the results deserved to be considered given the large number of patients with diabetes and multivessel coronary artery disease who are...
Source: Journal of the American College of Cardiology - March 16, 2015 Category: Cardiology Source Type: research

Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data.
CONCLUSION: Methotrexate at low doses, such those used for maintenance therapy of RA, predicted a decreased risk of CVE. Since methotrexate doesn't interfere with blood lipids, platelet aggregation or insulin resistance, the protective association may originate from mechanisms other than those exerted by antiplatelet drugs or statins. PMID: 25697810 [PubMed - as supplied by publisher]
Source: The Anatolian Journal of Cardiology - February 16, 2015 Category: Cardiology Authors: De Vecchis R, Baldi C, Palmisani L Tags: Anadolu Kardiyol Derg Source Type: research

Adiponectin, type 2 diabetes and cardiovascular risk
Conclusions In conclusion, increasing plasma adiponectin is associated with decreased risk of T2DM and subsequently reduced risk of CV events.
Source: European Journal of Preventive Cardiology - February 10, 2015 Category: Cardiology Authors: Lindberg, S., Jensen, J. S., Bjerre, M., Pedersen, S. H., Frystyk, J., Flyvbjerg, A., Galatius, S., Jeppesen, J., Mogelvang, R. Tags: Original scientific paper Source Type: research

The association of the treatment with glucagon-like peptide-1 receptor agonist exenatide or insulin with cardiovascular outcomes in patients with type 2 diabetes: a retrospective observational study
Background: To evaluate the association of treatment with glucagon-like peptide-1 (GLP-1) receptor agonist exenatide and/or insulin on macrovascular outcomes in patients with type 2 diabetes (T2DM). Methods: We conducted a retrospective longitudinal pharmaco-epidemiological study using large ambulatory care data to evaluate the risks of heart failure (HF), myocardial infarction (MI) and stroke in established T2DM patients who received a first prescription of exenatide twice daily (EBID) or insulin between June 2005 and May 2009, with follow-up data available until December 2012. Three treatment groups were: EBID with oral ...
Source: Cardiovascular Diabetology - January 24, 2015 Category: Cardiology Authors: Sanjoy PaulKerenaftali KleinDavid MaggsJennie Best Source Type: research

Age-Specific Performance of the Revised Cardiac Risk Index for Predicting Cardiovascular Risk in Elective Noncardiac Surgery Original Articles
Conclusions— In a nationwide unselected cohort, the performance of the RCRI was similar to that of the original cohort. Having ≥1 risk factor was of moderate sensitivity, but high negative predictive value for all ages.
Source: Circulation: Cardiovascular Quality and Outcomes - January 20, 2015 Category: Cardiology Authors: Andersson, C., Wissenberg, M., Jorgensen, M. E., Hlatky, M. A., Merie, C., Jensen, P. F., Gislason, G. H., Kober, L., Torp-Pedersen, C. Tags: Other diagnostic testing Original Articles Source Type: research

Asymmetric dimethylarginine and long-term adverse cardiovascular events in patients with type 2 diabetes: relation with the glycemic control
Conclusions: In patients with type 2 diabetes, ADMA might be an independent risk factor for long-term adverse cardiovascular events. However, ADMA was not correlated with serum HbA1c level, and in diabetic patients with HbA1c ?6.5%, elevated ADMA level was no longer associated with increased risk of long-term prognosis. Our findings suggested that the prognosis predictive value of ADMA in type 2 diabetes might be modified by the glycemic control.
Source: Cardiovascular Diabetology - December 3, 2014 Category: Cardiology Authors: Chiao-Po HsuPai-Feng HsuMing-Yi ChungShing-Jong LinTse-Min Lu Source Type: research

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial
Publication date: December 2014 Source:American Heart Journal, Volume 168, Issue 6 Author(s): Catherine M. Viscoli , Lawrence M. Brass , Antonio Carolei , Robin Conwit , Gary A. Ford , Karen L. Furie , Mark Gorman , Peter D. Guarino , Silvio E. Inzucchi , Anne M. Lovejoy , Mark W. Parsons , Peter N. Peduzzi , Peter A. Ringleb , Gregory G. Schwartz , J. David Spence , David Tanne , Lawrence H. Young , Walter N. Kernan Background Recurrent vascular events remain a major source of morbidity and mortality after stroke or transient ischemic attack (TIA). The IRIS Trial is evaluating an approach to secondary prevention based o...
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research

Hypertension in diabetes: optimal pharmacotherapy.
Authors: Biswas A, Alvarez A, Mukherjee D Abstract Hypertension is commonly associated with diabetes mellitus. The combination of hypertension with obesity and diabetes is a well recognized entity known as the metabolic syndrome, which shares a common pathophysiology of insulin resistance. The individual components of this syndrome act synergistically to substantially increase the risk of renal disease, stroke, coronary artery disease, and death. Hypertension increases both macrovascular and microvascular complications of diabetes such as neuropathy, nephropathy, coronary artery disease, stroke, and retinopathy. He...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - November 23, 2014 Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research